# Medical Drug Clinical Criteria

Subject: Lymphir (denileukin diftitox-cxdl)

 Document #:
 CC-0268
 Publish Date:
 10/10/2024

 Status:
 New
 Last Review Date:
 09/09/2024

# **Table of Contents**

<u>Overview</u> <u>Coding</u> <u>References</u>

Clinical Criteria Document History

#### **Overview**

This document addresses the use of Lymphir (denileukin diftitox-cxdl). Lymphir is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Denileukin diftitox was previously approved under the brand name Ontak but was withdrawn from the market in 2014 due to production issues.

The approval of Lymphir is based on results from the Phase 3 Pivotal Study 302 (NCT01871727) of CTCL patients who had previously received at least one systemic treatment. Eligible patients were required to have expression of CD25 on  $\geq$  20% of biopsied malignant cells by immunohistochemistry. The study excluded patients with significant cardiac disease or uncontrolled infections. Actual study patients received a median of 4 (min, max: 1, 18) prior anticancer therapies. The primary efficacy population includes 69 patients with stage I-III CTCL who were treated with denileukin diffitox-cxdl (9  $\mu$ g /kg/day). The primary efficacy outcome measure was Objective Response Rate (ORR), as assessed by an Independent Review Committee (IRC). The ORR was 36.2%, (95% CI: 25.0-48.7), with 8.7% achieving a Complete Response (CR).

Lymphir has a black box warning for capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as CLS. It is recommended to regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension and monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity. If Lymphir is withheld, resume treatment following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL.

### **Clinical Criteria**

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

## Lymphir (denileukin diftitox-cxdl)

Requests for Lymphir (denileukin diffitox-cxdl) may be approved if the following criteria are met:

- I. Individual has a diagnosis of cutaneous T-cell lymphoma (CTCL); AND
- II. Individual has relapsed or refractory disease after at least one prior systemic therapy; AND
- III. Individual has stage I to III disease; AND
- IV. Biopsied malignant cells have expression of CD25 on at least 20% of cells.

### Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**HCPCS** 

J9999 Not otherwise classified, antineoplastic drugs (Lymphir)

C9399 Unclassified drugs or biologics (Lymphir)

**ICD-10 Diagnosis** 

All diagnosis pend

# **Document History**

New: 09/09/2024 Document History:

> 09/09/2024 – Annual Review: New criteria for Lymphir. Coding Reviewed: Add HCPCS J9999 and C9399 for Lymphir. All diagnosis pend for NOC codes.

#### References

- 1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Updated periodically.
- 2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- 3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
- 4. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp.
  - a. T-Cell Lymphomas. V4.2024. Revised May 28, 2024.
  - b. P rimary Cutaneous Lymphomas. V2.2024. Revised May 6, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association